Business Strategy & Portfolio Upgrade - The company aims to upgrade its business portfolio with a new growth strategy, focusing on winning businesses rooted in organic synthesis technology and cultivating new growth businesses[2, 12, 14] - The company is focusing on three blockbuster candidates in the chemicals business, aiming for sales of several tens of billions of yen by 2030[16, 17] - The company aims to expand its biorationals business to 150 billion yen by FY2030, a 2X increase from 70 billion yen in FY2024[36] - The company targets a 20% market share in cutting-edge semiconductor resist[47] Financial Targets & Capital Efficiency - The company's financial targets for FY2027 include a core operating income of 200 billion yen, ROE of 8%, ROIC of 6%, and a D/E ratio of approximately 0.8X[12] - The company expects a dividend payout ratio of over 30% during the new plan period, aiming for 24 yen/share or more per year early in the future[136, 137] Structural Reforms & Resilience - Petro Rabigh is undergoing financial improvements, including a $1.5 billion loan write-off and a $702 million contribution from the sale of approximately 22.5% of PRC to Aramco[111, 113] - The company is integrating its domestic PP and LLDPE businesses into Prime Polymer, expecting cost reductions of over 8 billion yen per year[115, 119] Advanced Medical Solutions - The company is deploying a winning CDMO strategy leveraging its strengths in advanced small molecule APIs and oligonucleotide CDMO, focusing on high-purity long-chain nucleotides[55, 69] - The company aims for its Parkinson's disease therapy using iPS cells to grow into a blockbuster with 100 billion yen in sales in the 2030s[102]